0001797199-20-000003.txt : 20201110
0001797199-20-000003.hdr.sgml : 20201110
20201110200719
ACCESSION NUMBER: 0001797199-20-000003
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201106
FILED AS OF DATE: 20201110
DATE AS OF CHANGE: 20201110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GORENSTEIN MICHAEL RYAN
CENTRAL INDEX KEY: 0001797199
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38403
FILM NUMBER: 201302668
MAIL ADDRESS:
STREET 1: 111 PETER STREET, SUITE 300
CITY: TORONTO
STATE: A6
ZIP: M5V 2G9
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cronos Group Inc.
CENTRAL INDEX KEY: 0001656472
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 111 PETER STREET
STREET 2: SUITE 300
CITY: TORONTO
STATE: A6
ZIP: M5V 2G9
BUSINESS PHONE: (416) 504-0004
MAIL ADDRESS:
STREET 1: 111 PETER STREET
STREET 2: SUITE 300
CITY: TORONTO
STATE: A6
ZIP: M5V 2G9
FORMER COMPANY:
FORMER CONFORMED NAME: PharmaCan Capital Corp.
DATE OF NAME CHANGE: 20151021
4
1
wf-form4_160505682132696.xml
FORM 4
X0306
4
2020-11-06
0
0001656472
Cronos Group Inc.
CRON
0001797199
GORENSTEIN MICHAEL RYAN
111 PETER STREET, SUITE 300
TORONTO
A6
M5V 2G9
ONTARIO, CANADA
1
1
0
0
Executive Chairman
COMMON SHARES
2020-11-06
4
S
0
1181499
7.1621
D
725298
D
COMMON SHARES
2020-11-06
4
S
0
107851
7.9177
D
617447
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.70 to $7.69, inclusive. The reporting person undertakes to provide to Cronos Group Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
The total number of shares beneficially owned was misreported on the reporting person's Form 3 filed on December 31, 2019, which overreported the amount of beneficially owned shares by 100 shares. The number stated in this filing reflects the correction of the misreported amount.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.695 to $8.095, inclusive.
/s/ Eileen Uy, as attorney-in-fact for Michael R. Gorenstein
2020-11-10